Gain Therapeutics reports brain target engagement in Parkinson's study
Tweet Send to a Friend
Gain Therapeutics Inc. (NASDAQ: GANX) announced that its Phase 1b clinical study of GT-02287 showed a reduction in glucosylsphingosine (GluSph) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
